Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Darolutamide Tablets, 300 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Darolutamide Tablets, 300 mg.".